Back | Next |
home / stock / nktx / nktx message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: NKTX 141% v109M C18.72 f33M H18.95 gapN held yet choppy | znewcar1 | investorshangout | 04/26/2022 1:08:28 AM |
Price target is 109. Wouldnt consider 18 high | rynlrt | investorshub | 04/26/2022 12:07:55 AM |
thats assuming a high price of 18 | TheFinalCD | investorshub | 04/25/2022 8:25:50 PM |
That's only about 10M shares if @ 18.00 | crudeoil24 | investorshub | 04/25/2022 8:21:50 PM |
Turn your monitor upside down! lol | crudeoil24 | investorshub | 04/25/2022 8:10:11 PM |
UP ON OFFERING NEWS | TheFinalCD | investorshub | 04/25/2022 8:09:01 PM |
I see > $NKTX @ 19.84 now. Probably | crudeoil24 | investorshub | 04/25/2022 8:06:59 PM |
$NKTX Nkarta Announces Proposed Public Offering of Common Stock | TheFinalCD | investorshub | 04/25/2022 8:02:18 PM |
znewcar1: oard created in 2020 frow what looks like a BO38 to HH79.16 YL7.55 morning pop over 15 | znewcar1 | investorshangout | 04/25/2022 7:34:48 PM |
Thank you ! I wish Elon Musk buy | crudeoil24 | investorshub | 04/25/2022 7:28:39 PM |
18.94 CONGRAT$ | TheFinalCD | investorshub | 04/25/2022 7:26:48 PM |
PT > 109.00 > Mizuho Maintain Buys On | crudeoil24 | investorshub | 04/25/2022 7:26:07 PM |
$NKTX > PHI SLAMMA JAMA! | crudeoil24 | investorshub | 04/25/2022 7:18:13 PM |
$NKTX > 17.94 | crudeoil24 | investorshub | 04/25/2022 6:57:34 PM |
znewcar1: ML7.55l HOD16.46 a gap fill to 16.35+19.75 | znewcar1 | investorshangout | 04/25/2022 6:49:16 PM |
Another group plans to test an anti-CD70 CAR-NK | jondoeuk | investorshub | 04/25/2022 6:01:10 PM |
More (preclinical data) from the same group | jondoeuk | investorshub | 04/25/2022 5:55:06 PM |
A PhI is planned | jondoeuk | investorshub | 04/25/2022 5:52:04 PM |
MICA and MICB, as well as ULBP 1-6 | jondoeuk | investorshub | 04/25/2022 5:45:19 PM |
Let's go $NKTX ..... | crudeoil24 | investorshub | 04/25/2022 4:04:32 PM |
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing...
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data ...